Skip to Content
Jump to the top of the page

Investment Banking

The Quarterly Rx: Q2 2023 U.S. Biopharma Recap

Biopharma markets closed the first half of 2023 with renewed optimism and an encouraging outlook for the rest of the year. That comes as major market indices have trended upward—with biopharma emerging as the most heavily weighted sector in the Russell 2000—despite macro concerns following the regional banking crisis.

Public financing markets have warmed, but private companies continue to face challenging decisions amid a slow IPO market and selective private financing market. Simultaneously, SMID-cap M&A helped recycle capital in the sector.

William Blair’s Biopharma team shares perspectives in the Quarterly Rx: Q2 2023 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

More News and Insights

  • Tracking Job Openings and Staffing Demand Trends

    Global services analyst Trevor Romeo, CFA discusses the impact of recent economic uncertainties on the staffing industry, highlighting key trends and challenges faced by companies and exploring the evolving landscape of job openings and the future of staffing.

    Listen to the podcast
  • William Blair Initiates Coverage of Two Biotech Companies

    William Blair initiated research coverage of Context Therapeutics Inc. (CNTX $0.84) and Xencor, Inc. (XNCR $9.70), two biotech companies focused on the development of T-cell engagers (TCEs) for solid tumor indications.

    Read more
  • Zillow Group, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Zillow Group, Inc. (Z $62.47), the leader among home search portals in visitor traffic.

    Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures